# Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

> **NCT04269707** · PHASE3 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Iron Deficiency Anemia

## Interventions

- **DRUG:** Ferric carboxymaltose

## Key facts

- **NCT ID:** NCT04269707
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-19
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-01-29
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269707, "Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04269707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*